Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07562152 · ClinicalTrials.gov registry record · Phase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase 3 study, sponsored by Immuneering Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 510
- Enrollment target
NCT07562152: Recruiting Phase 3 study, sponsored by Immuneering Corporation.
NCT07562152 is a Phase 3 study that is actively recruiting participants, run by Immuneering Corporation. The registered enrollment target is 510 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07562152, a Phase 3 study, is actively recruiting participants, sponsored by Immuneering Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 510 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Primary Outcome
The OS of participants with atebimetinib in combination with mGnP versus GnP
Interventions
- DRUG Atebimetinib
- DRUG GnP
- DRUG mGnP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2026-06 |
| Est. Completion | 2029-02 |
| Phase | Phase 3 |
What NCT07562152 shows while recruiting
NCT07562152 is an interventional study that assigns participants to a tested intervention. The registered 510 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% lower).
The record links to 0 conditions, and to 3 interventions - of which Atebimetinib is the first listed.
NCT07562152 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07562152 about?
NCT07562152 is a clinical study titled "Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma". The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
What is the current status of trial NCT07562152?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 510 participants. The study started on 2026-06. Estimated completion is 2029-02.
What interventions are being tested in trial NCT07562152?
The interventions under investigation include: Atebimetinib (DRUG), GnP (DRUG), mGnP (DRUG).
Who is sponsoring clinical trial NCT07562152?
This trial is sponsored by Immuneering Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07562152's enrollment target sits among peer trials
510 729th of 2000 higher than 1,264 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03922542 · 510 participants · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
- NCT04634552 · 510 participants · Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- NCT05164744 · 510 participants
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
- NCT05451004 · 510 participants · Phase 3
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia